SG11202100137TA - PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 - Google Patents
PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8Info
- Publication number
- SG11202100137TA SG11202100137TA SG11202100137TA SG11202100137TA SG11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibiting
- pyridazine compounds
- pyridazine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695510P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/041026 WO2020014243A1 (en) | 2018-07-09 | 2019-07-09 | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100137TA true SG11202100137TA (en) | 2021-02-25 |
Family
ID=69143022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100137TA SG11202100137TA (en) | 2018-07-09 | 2019-07-09 | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11993581B2 (en) |
| EP (1) | EP3820860A4 (en) |
| JP (1) | JP2021531256A (en) |
| KR (1) | KR20210019119A (en) |
| CN (1) | CN112689629B (en) |
| AU (1) | AU2019302534B2 (en) |
| CA (1) | CA3105748A1 (en) |
| SG (1) | SG11202100137TA (en) |
| WO (1) | WO2020014243A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| BR112022010924A2 (en) | 2019-12-06 | 2022-09-06 | Vertex Pharma | SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATION |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| JP2024520649A (en) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Solid dosage forms and administration regimens comprising (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| CN117794919A (en) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators |
| CN117794920A (en) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators |
| CN117858875A (en) | 2021-06-04 | 2024-04-09 | 沃泰克斯药物股份有限公司 | Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators |
| WO2023138599A1 (en) | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | Aromatic fused ring nav1.8 inhibitor, and use thereof |
| WO2023160509A1 (en) * | 2022-02-25 | 2023-08-31 | 中国科学院上海药物研究所 | Amidine derivative compound, and preparation method therefor and use thereof |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023263309A1 (en) | 2022-04-25 | 2024-12-05 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2114654T3 (en) | 1993-06-08 | 1998-06-01 | Vertex Pharma | PIRIDAZINES AS INHIBITORS OF THE INTERLEUKIN-1BETA CONVERSION ENZYME. |
| JP2004238361A (en) | 2003-02-07 | 2004-08-26 | Tosoh Corp | Pyrimidine-5-carboxamide derivative, its intermediate and method for producing the same |
| AR045238A1 (en) | 2003-08-08 | 2005-10-19 | Vertex Pharma | USEFUL COMPOUNDS AS INHIBITORS OF IONIC CHANNELS REGULATED BY VOLTAGE |
| RU2006118312A (en) | 2003-10-28 | 2007-12-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | BENZIMIDAZOLE USEFUL AS ION CHANNEL MODULATORS |
| RU2007146769A (en) | 2005-05-16 | 2009-06-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | BICYCLIC DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF ION CHANNELS |
| CN101238109B (en) | 2005-06-09 | 2011-12-14 | 沃泰克斯药物股份有限公司 | Indane derivatives as modulator of ion channels |
| US7855220B2 (en) | 2005-09-09 | 2010-12-21 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| EP1934191B1 (en) | 2005-10-12 | 2012-03-28 | Vertex Pharmaceuticals, Inc. | Biphenyl derivatives as modulators of voltage gated ion channels |
| MX2009003876A (en) | 2006-10-12 | 2009-05-11 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents. |
| MX2010003866A (en) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels. |
| CA2701766A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| EP2212290B1 (en) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| CN102203065B (en) | 2008-10-29 | 2014-07-09 | 霍夫曼-拉罗奇有限公司 | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
| AU2009308982A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| AR077252A1 (en) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS |
| CA2771472A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| HUE028983T2 (en) | 2010-05-06 | 2017-01-30 | Vertex Pharma | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| AU2011311238A1 (en) * | 2010-10-05 | 2013-04-04 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| CN106008504A (en) | 2011-02-02 | 2016-10-12 | 沃泰克斯药物股份有限公司 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
| MX2013009393A (en) | 2011-02-18 | 2013-08-29 | Vertex Pharma | Chroman - spirocyclic piperidine amides as modulators of ion channels. |
| CA2828456C (en) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| JP6088443B2 (en) | 2011-03-14 | 2017-03-01 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| NZ627259A (en) | 2012-01-16 | 2016-12-23 | Vertex Pharma | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| US9624208B2 (en) * | 2012-10-26 | 2017-04-18 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| CA2898650C (en) | 2013-01-31 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| WO2014151393A2 (en) | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| HUE037876T2 (en) | 2013-07-19 | 2018-09-28 | Vertex Pharma | Sulfonamides as modulators of sodium channels |
| TWI668226B (en) | 2013-12-13 | 2019-08-11 | 美商維泰克斯製藥公司 | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2015214366B2 (en) | 2014-02-06 | 2019-04-18 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| CN106715418A (en) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | Therapeutic compounds and methods of use thereof |
| MA41598A (en) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES |
| ES2902676T3 (en) * | 2017-02-13 | 2022-03-29 | Bristol Myers Squibb Co | Aminotriazolopyridines as kinase inhibitors |
| BR112020000553A2 (en) | 2017-07-11 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | carboxamides as sodium channel modulators |
-
2019
- 2019-07-09 SG SG11202100137TA patent/SG11202100137TA/en unknown
- 2019-07-09 AU AU2019302534A patent/AU2019302534B2/en active Active
- 2019-07-09 JP JP2021500459A patent/JP2021531256A/en active Pending
- 2019-07-09 US US17/256,784 patent/US11993581B2/en active Active
- 2019-07-09 KR KR1020217003942A patent/KR20210019119A/en unknown
- 2019-07-09 EP EP19833110.0A patent/EP3820860A4/en active Pending
- 2019-07-09 CA CA3105748A patent/CA3105748A1/en active Pending
- 2019-07-09 CN CN201980058833.4A patent/CN112689629B/en active Active
- 2019-07-09 WO PCT/US2019/041026 patent/WO2020014243A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021531256A (en) | 2021-11-18 |
| CN112689629B (en) | 2024-04-23 |
| CA3105748A1 (en) | 2020-01-16 |
| US20210139456A1 (en) | 2021-05-13 |
| WO2020014243A1 (en) | 2020-01-16 |
| AU2019302534B2 (en) | 2024-10-03 |
| US11993581B2 (en) | 2024-05-28 |
| EP3820860A4 (en) | 2022-04-20 |
| AU2019302534A1 (en) | 2021-01-28 |
| KR20210019119A (en) | 2021-02-19 |
| EP3820860A1 (en) | 2021-05-19 |
| CN112689629A (en) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100137TA (en) | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 | |
| IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| SG11202100130QA (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
| IL288236A (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| EP3873468A4 (en) | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors | |
| IL283853A (en) | Novel crispr-cas systems for genome editing | |
| IL289290A (en) | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof | |
| EP3583507A4 (en) | Blockchain-based admission processes for protected entities | |
| ZA202213566B (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| EP4167993A4 (en) | 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors | |
| EP4167994A4 (en) | 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors | |
| EP3578555A4 (en) | Diphenylaminopyrimidine compound for inhibiting kinase activity | |
| PT3720442T (en) | Inhibiting mutant idh-1 | |
| GB201810965D0 (en) | Phosphoantigen prodrug compounds | |
| PT3589637T (en) | Compounds useful for inhibiting ror-gamma-t | |
| EP4028708C0 (en) | Lock system | |
| EP3820847A4 (en) | Improved compounds for myc inhibition | |
| GB2576589B (en) | Lock mechanism | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| GB2572742B (en) | Locking mechanism | |
| PT3589638T (en) | Compounds useful for inhibiting ror-gamma-t | |
| LT3720442T (en) | Inhibiting mutant idh-1 | |
| EP3824155C0 (en) | Lock mechanism | |
| GB201819687D0 (en) | Mrbr.5 | |
| HUE053462T2 (en) | Locking mechanism |